CTCE-9908

CTCE-9908 is a synthetic peptide analog of stromal cell-derived factor 1 (SDF‑1, also known as CXCL12) and functions as an antagonist of the C-X-C chemokine receptor type 4 (CXCR4). By selectively binding to CXCR4, it blocks the interaction between CXCR4 and its ligand SDF‑1, thereby inhibiting downstream signaling pathways that promote tumor cell proliferation, survival, migration, invasion, angiogenesis, and metastasis. Overexpression of CXCR4 is associated with poor prognosis in several cancers. Preclinical studies have shown that CTCE‑9908 can reduce primary tumor growth and metastatic spread in various cancer models including prostate cancer, bone cancer, skin cancer, lung cancer, melanoma, glioblastoma, osteosarcoma and esophageal carcinoma. Early-phase clinical trials have demonstrated tolerability and some evidence of disease stabilization in late-stage cancer patients[2][5][6][7][10]. The drug was developed by Chemokine Therapeutics.

Other names

SDF-1 receptor antagonist PTX-9908SDF1 receptor antagonist PTX-9908SDF 1 receptor antagonist PTX-9908